Inspiratory and expiratory muscle strength changes are related to a functional capacity change in hospitalized patients undergoing hematopoietic stem cell transplantation

Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) have to worsen of functional capacity during hospitalization. However, it is not known whether the respiratory muscle strength is related to functional capacity.Objective: We hypothesized that functional capacity change is correlated to respiratory muscle strength changes in patients during hospitalization for HSCT.Methods: This is a prospective, observational study. Thirty one patients (18 males; 45 years) hospitalized for HSCT were eligible for this study. Respiratory muscle strength (Maximal Inspiratory Pressure - MIP and Maximal Expiratory Pressure - MEP; MVD300 Globalmed®) and functional capacity (6-Minute Step Test – 6MST) were assessed at admission (before HSCT) and hospital discharge (after HSCT). The delta values (discharge minus admission hospital) were subjected to a simple linear regression (P
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Physiotherapists Source Type: research

Related Links:

High dose chemotherapy followed by autologous stem cell transplantation (ASCT) offers a cure in the relapsed setting in both Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Additionally, it remains a first-line standard of care in multiple myeloma (MM) patients whom are eligible for ASCT. However, the management of these hematologic malignancies continues to rapidly evolve with non-cytotoxic therapeutic options such as development of new cellular therapies. These developments underscore the importance of monitoring immune reconstitution after ASCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 476 Source Type: research
KIR B(x) haplotype donors have been reported to improve outcomes in patients (pts) receiving unrelated donors (URD) for myeloid malignancies, non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Donors are categorized as KIR “Best” or “Better”. Our center performs donor KIR genotyping and haplotype assignment routinely as part of our URD evaluation for pts undergoing transplantation for myeloid disorders, NHL and MM. When presented with multiple equivalently HLA matched URDs, our physicians will prioritize KIR B (X) donors over KIR A/A donors.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 447 Source Type: research
ConclusionsThis study is one of the first to apply the EORTC QLU-C10D to a heterogeneous group of cancer patients. Results can be used to more efficiently target care towards factors influencing HRQoL. Furthermore, it enhances our understanding of how the EORTC QLU-C10D performs across cancer types, supporting its use in cost –utility analyses.
Source: Quality of Life Research - Category: Health Management Source Type: research
Research shows several exercises can be effective against these cancers: breast, colon, endometrial, kidney, liver, multiple myeloma and non-Hodgkin lymphoma.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alexandre E. Malek, Yago Nieto, Ariel D. Szvalb, Shaheer Siddiqui, Mehnaz A. Shafi, Jessica P. Hwang, Issam I. Raad, Harrys A. Torres
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 December 2019Source: Clinica Chimica ActaAuthor(s): Nidhi Gupta, Aparna Sharma, Alpana SharmaAbstractMultiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin lymphoma and is manifested by uncontrolled proliferation and accumulation of abnormal plasma cells in the bone marrow (BM). The incidence along with deaths associated with MM is on rise due to lack of an effective diagnosis at an early stage. The identification of MM decades ago marks the adoption of certain conventional markers such as plasma cell percentage in BM, serum protein electrophoresis f...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Abstract Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin lymphoma and is manifested by uncontrolled proliferation and accumulation of abnormal plasma cells in the bone marrow (BM). The incidence along with deaths associated with MM is on rise due to lack of an effective diagnosis at an early stage. The identification of MM decades ago marks the adoption of certain conventional markers such as plasma cell percentage in BM, serum protein electrophoresis for M-band and urinary Bence-Jones protein. This was then followed by utilization of β2 microglobulin and serum album...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alexandre E. Malek, Yago Nieto, Ariel D. Szvalb, Shaheer Siddiqui, Mehnaz A. Shafi, Jessica P. Hwang, Issam I. Raad, Harrys A. Torres
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the United States Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of sever al other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL).1 Recently, ibrutinib plus venetoclax have been found to be effective as first-line treatment for high-risk and older patients with CLL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Physiotherapy | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study | Transplants